Technical Articles

This article systematically elaborates on the molecular structure and functional characteristics of CD22 (Siglec-2) as an inhibitory co-receptor on the surface of B cells, its physiological role in B cell development and signal regulation, its widespread expression profile in B cell malignancies, and the clinical progress of monoclonal antibodies, antibody-drug conjugates, and CAR-T cell therapies developed based on this foundation. Additionally, it introduces the detection and application value of fluorescently labeled recombinant proteins.